A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-cancer Pain

Trial Profile

A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-cancer Pain

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs NKTR 181 (Primary)
  • Indications Back pain; Pain
  • Focus Adverse reactions; Registrational
  • Acronyms SUMMIT-LTS
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2016 Planned number of patients changed from 600 to 640.
    • 03 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top